US FDA Expands Novartis Drug Use
The US Food and Drug Administration has approved the Novartis drug remibrutinib to treat adults with a chronic skin condition causing itchy welts. The approval expands the drug's use beyond chronic spontaneous urticaria following positive trial results.
Xurve View
Insights:
Xurve View
NOVARTIS AG-REG secured United States regulatory approval on Wednesday afternoon to expand the use of its drug remibrutinib for a chronic skin condition. The Swiss drugmaker gained the green light for adult patients suffering from symptomatic dermographism. The decision adds momentum to the drug's pipeline following recent setbacks in the company's cardiovascular and muscle disease therapies.
